Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Antineoplastic agents >  Selumetinib Sulfate

Selumetinib Sulfate

Basic information Safety Supplier Related

Selumetinib Sulfate Basic information

Product Name:
Selumetinib Sulfate
Synonyms:
  • Selumetinib Sulfate
  • 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethoxy)amide hydrogen sulphate
  • 5-((4-Bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide sulfate
  • Selumetinib sulfate (AZD6244 sulfate)
  • Selumetinib sulfate,AZD-6244
  • Smetinib sulfate
  • ARRY-142886 sulfate
CAS:
943332-08-9
MF:
C17H17BrClFN4O7S
MW:
555.76
Mol File:
943332-08-9.mol
More
Less

Selumetinib Sulfate Chemical Properties

storage temp. 
Store at -20°C
solubility 
DMSO: 50 mg/mL (89.97 mM); Water: < 0.1 mg/mL (insoluble)
form 
Solid
color 
Light yellow to yellow
InChIKey
GRKFGZYYYYISDX-UHFFFAOYSA-N
SMILES
S(O)(O)(=O)=O.N(C1C=CC(Br)=CC=1Cl)C1C(=C2N=CN(C)C2=CC=1C(=O)NOCCO)F
CAS DataBase Reference
943332-08-9
More
Less

Selumetinib Sulfate Usage And Synthesis

Uses

Selumetinib Sulfate (Koselugo) is a selective ATP-noncompetitive MEK1/2 inhibitor developed by Array BioPharma for the treatment of neurofibromatosis type 1 (NF1).

Trade name

Koselugo

Mechanism of action

As a MEK1/2 inhibitor, Selumetinib Sulfate inhibits the activity of mitogen-activated protein kinase (MEK), thereby affecting the RAS/RAF/MEK/ERK signaling pathway, which plays a key role in the occurrence and development of NF1-related tumors.

Synthesis

The synthesis started from 2,3,4-trifluorobenzoic acid (345). Nitration of 345 gave compound 346. SNAr amination of 346 gave compound 348. Esterification of 348 gave the carboxylic acid derivative 347. Final SNAr amination of 347. Reduction of the nitro group in 349 with Pd(OH)2 and in situ condensation with formic acid gave 1H-benzimidazole 350 in good yield. Sequential halogenation of 350 with NBS and NCS gave the 4-bromo-2-chloroaniline group 352. Methylation of the 1H-benzimidazole gave 353 in moderate yield. Saponification (hydrolysis) of the ester group in 353 gave compound 356. 356 was reacted with hydroxylamine 355 using an EDCI/HOBt-mediated amidation reaction to give amide 356. Acid hydrolysis of the vinyl ether in 356 gave the alcohol 357 quantitatively. Finally, selumetinib sulfate was obtained by salt formation with sulfuric acid H2SO4 in 2-butanone.

Selumetinib SulfateSupplier

Wuhan Linglingjiu Biotechnology Co., Ltd Gold
Tel
15623309010
Email
1287744812@qq.com
wuhan dingxingtong Chemical Technology Co., Ltd Co., Ltd Gold
Tel
027-59207796 13429867250
Email
w13429867250@163.com
Shanghai Kuanghao Chemistry Technology Co., Ltd. Gold
Tel
1590082856 15900820856
Email
83219210@qq.com
Nanjing Dulai Biotechnology Co., Ltd.
Tel
025-846993838003-8003 18013301590
Email
njduly@126.com
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185
Email
sales-cpd@caerulumpharma.com